These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 29636628)
1. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Silvado CE; Terra VC; Twardowschy CA Pharmgenomics Pers Med; 2018; 11():51-58. PubMed ID: 29636628 [TBL] [Abstract][Full Text] [Related]
2. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067 [TBL] [Abstract][Full Text] [Related]
3. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis . Liao K; Liu Y; Ai CZ; Yu X; Li W Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024 [TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. Wu X; Liu W; Zhou W J Clin Pharm Ther; 2018 Jun; 43(3):408-413. PubMed ID: 29274302 [TBL] [Abstract][Full Text] [Related]
5. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]. Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425 [TBL] [Abstract][Full Text] [Related]
6. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Chang WC; Hung SI; Carleton BC; Chung WH Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242 [TBL] [Abstract][Full Text] [Related]
7. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219 [TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Kesavan R; Narayan SK; Adithan C Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258 [TBL] [Abstract][Full Text] [Related]
9. Association of John S; Balakrishnan K; Sukasem C; Anand TCV; Canyuk B; Pattharachayakul S J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442381 [TBL] [Abstract][Full Text] [Related]
10. Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects. Guevara N; Maldonado C; Uría M; González R; Ibarra M; Alvariza S; Carozzi A; Azambuja C; Fagiolino P; Vázquez M Pharmaceuticals (Basel); 2017 Aug; 10(3):. PubMed ID: 28820457 [TBL] [Abstract][Full Text] [Related]
11. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277 [TBL] [Abstract][Full Text] [Related]
12. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Franco V; Perucca E Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375 [TBL] [Abstract][Full Text] [Related]